Oxytocin, Couple Interaction and Wound Healing

This study has been completed.
Sponsor:
Collaborator:
Swiss National Science Foundation
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01594775
First received: May 7, 2012
Last updated: February 24, 2014
Last verified: February 2014
  Purpose

effects of intranasal oxytocin and couple interaction on wound healing.

  • Trial with medicinal product

Condition Intervention Phase
Healthy Volunteers
Drug: Syntocinon (Oxytocin) nasal spray
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • wound size [ Time Frame: seven days ] [ Designated as safety issue: No ]
    wound healing process within seven days after wounding


Enrollment: 160
Study Start Date: October 2011
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: nasal spray Drug: Syntocinon (Oxytocin) nasal spray
two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
Placebo Comparator: Placebo Drug: Placebo
two-times daily self-administration of nasal spray containing placebo during five days after wounding.

  Eligibility

Ages Eligible for Study:   21 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • healthy heterosexual couples
  • in a stable relationship since > 1 year

Exclusion criteria: pregnancy

  • breast feeding
  • heavy smoking (> 5 cigarettes/d)
  • extensive skin disease
  • artificial UV irradiation during < 3 months before study inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01594775

Locations
Switzerland
University Hospital Zurich, Dept. of Dermatology
Zurich, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Swiss National Science Foundation
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
Principal Investigator: Severin Laeuchli, MD University Hospital Zurich, Division of Dermatology
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01594775     History of Changes
Other Study ID Numbers: KEK-ZH-NR: 2009-0063
Study First Received: May 7, 2012
Last Updated: February 24, 2014
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
Oxytocin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on July 20, 2014